➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Merck
Express Scripts
McKesson
Harvard Business School

Last Updated: October 22, 2020

DrugPatentWatch Database Preview

Tocilizumab - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for tocilizumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
The Swedish Research CouncilPhase 4
Vastra Gotaland RegionPhase 4
Noordwest ZiekenhuisgroepPhase 2

See all tocilizumab clinical trials

Recent Litigation for tocilizumab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Celgene Corporation v. Aurobindo Pharma Limited2018-07-06
CELGENE CORPORATION v. EMCURE PHARMACEUTICALS LTD.2018-06-28
AMGEN INC v. SANDOZ INC.2018-06-26

See all tocilizumab litigation

PTAB Litigation
PetitionerDate
Crescendo Bioscience, Inc2017-04-12

See all tocilizumab litigation

Pharmacology for tocilizumab

Patent Text Search: US Patents for tocilizumab

These patents were identified by searching patent claims

Supplementary Protection Certificates for tocilizumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
20C/505 Belgium   Start Trial PRODUCT NAME: UPADACITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/19/1404 20191218
2020505 Lithuania   Start Trial PRODUCT NAME: UPADACITINIBAS; REGISTRATION NO/DATE: EU/1/19/1404 20191216
90010-6 Sweden   Start Trial PRODUCT NAME: UPADACITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/19/1404 20191218
2020000011 Germany   Start Trial PRODUCT NAME: UPADACITINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1404 20191216
2020000000022 Italy   Start Trial PRODUCT NAME: UPADACITINIB IN QUALSIASI FORMA PROTETTA DAL BREVETTO DI BASE(RINVOQ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1404, 20191218
1035 Netherlands   Start Trial PRODUCT NAME: UPADACITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1404 20191218
C00149 Luxembourg   Start Trial PRODUCT NAME: UPADACITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/19/1404 20191218
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Baxter
Merck
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.